TSPOAP1 and pancreatic ductal adenocarcinoma: In the present study, we identified that overexpressing TSPOAP1‐AS1 had a better prognosis in NSCLC patients, which was in agreement with previous studies in pancreatic ductal adenocarcinoma and LUAD.38, 39